Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Canceled)

2. (Currently amended) The method of claim [[1]] ~~50~~, wherein the ligand is a flavone.

3. (Currently amended) The method of claim [[1]] ~~50~~, wherein the ligand is an aurone.

4. (Currently amended) The method of claim [[1]] ~~50~~, wherein the ligand is a T4 analog.

5-49. (Canceled)

~~50~~. (New) A method of assaying a translation product of a mutant ΔTRα2 gene, the method comprising

(a) providing a test cell that comprises p29 vesicles and a mutant ΔTRα2 translation product;

(b) contacting the test cell with a labeled ΔTRα2 ligand for a time sufficient to permit binding to the translation product; and

(c) measuring the amount, location, or rate of transit of the ligand in the test cell compared to the amount, location, or rate of transit of the ligand in a control cell that does not comprise a mutant ΔTRα2 translation product.

~~51~~. (New) The method of claim ~~50~~, wherein the cell is a neuron.

6 52. (New) The method of claim 50, wherein the cell is an astrocyte.

7 53. (New) The method of claim 50, wherein the amount of the ligand in the cell is measured.

8 54. (New) The method of claim 50, wherein the location of the ligand in the cell is measured.

9 55. (New) The method of claim 50, wherein the rate of transit of the ligand in the cell is measured.

10 56. (New) The method of claim 50, wherein the control cell comprises a wild type ΔTRα2 protein, and a decrease in the amount location, or rate of transit of the ligand in the test cell compared to the control indicates a decrease in the ability of the translation product to transport a vesicle compared to a wild type ΔTRα2 protein.